Clinical Trial

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2025-03-20; most recent amendment 2026-07-07.
Status change: Not Yet Recruiting → Recruiting 2025-05-05
Trial Details
NCT Number NCT06897930
Lead Sponsor AstraZeneca
Conditions Lupus Erythematosus, Systemic
Enrollment 150 participants
Start Date 2025-04-21
Primary Completion 2029-05-01 (estimated)
Study Completion 2029-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-12